Form 4: Organogenesis Director Sells 200,000 Shares

Organogenesis Holdings Inc. Director Glenn H. Nussdorf reported the sale of 200,000 Class A Common Stock shares for approximately $1.027 million.

Summary

• Glenn H. Nussdorf, a Director of Organogenesis Holdings Inc. (ORGO), sold 200,000 shares of Class A Common Stock.
• The transaction occurred on December 16, 2025, and was executed pursuant to a Rule 10b5-1(c) plan.
• The shares were sold at a weighted-average price of $5.1353 per share, with individual transaction prices ranging from $5.10 to $5.24.
• The total value of the shares sold amounts to approximately $1,027,060.
• Following this transaction, Mr. Nussdorf directly beneficially owns 2,565,591 shares of Class A Common Stock.
• Additionally, Mr. Nussdorf indirectly beneficially owns 918,680 shares through the GN 2016 Family Trust, 7,928,570 shares through the GN 2016 Organo 10-Year GRAT, and 335,719 shares through the Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998, totaling 9,182,969 indirect shares.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a director selling a significant number of shares. However, the pre-planned nature of the sale via a 10b5-1 plan mitigates some of the immediate negative implications, preventing a lower score.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction rather than a reaction to recent non-public information, which can mitigate negative market perception.

Negatives

• A Director selling a significant number of shares (200,000) can be interpreted by the market as a potential lack of confidence in the company's future prospects or a desire for personal diversification.

Risks

• Insider selling, particularly by a director, can sometimes signal potential headwinds or a less optimistic outlook for the company, which could lead to negative investor sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report does not provide information to analyze broader industry trends or competitor activities. It focuses solely on the individual's stock transaction.

Related Party Transactions

• Glenn H. Nussdorf indirectly beneficially owns shares through the GN 2016 Family Trust, GN 2016 Organo 10-Year GRAT, and Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998.

Stakeholder Impact

• Shareholders may view the director's sale as a negative signal, potentially impacting investor confidence and the company's stock price.
• Employees and other stakeholders might monitor such transactions for insights into management's perception of the company's future.

Key Dates

Recommendation

While insider selling by a director can be a negative signal, this transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new, adverse information. Investors should monitor for further insider activity and evaluate the company's fundamental performance rather than reacting solely to this single transaction. A 'hold' recommendation is appropriate given the context, suggesting investors maintain their current positions while observing future developments.

Keywords

Organogenesis, ORGO, Insider Trading, Form 4, Stock Sale, Director, Glenn Nussdorf, Equity Transaction, 10b5-1 Plan